Radionuclide development at BNL for nuclear medicine therapy.
Radionuclides with medium energy beta emission and a several day half-life have often been viewed as attractive candidates for radioimmunotherapy. Among the most promising in this category are 47Sc, 67Cu, 153Sm, 188Re, and 199Au. The production of 67Cu, 153Sm, 199Au at BNL is summarized and the development of the latest candidate for this application, 47Sc, is described in detail. We also summarize the development of another important therapeutic radionuclide, 117mSn for bone pain palliation.
Mausner
L F
LF
Brookhaven National Laboratory, Medical Department, Upton, NY 11973-5000, USA.
Kolsky
K L
KL
Joshi
V
V
Srivastava
S C
SC
D003301:Copper Radioisotopes; D006050:Gold Radioisotopes; D009683:Nuclear Medicine / Q000379:methods*; D011868:Radioisotopes / Q000737:chemistry* / Q000627:therapeutic use*; D012493:Samarium; D012538:Scandium; D014004:Tin Radioisotopes
D003301:Copper Radioisotopes; D006050:Gold Radioisotopes; D011868:Radioisotopes; D014004:Tin Radioisotopes; D012493:Samarium; D012538:Scandium